ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
Policymakers Detail Legislative Priorities Ahead of Midterm Elections
Regardless of which party controls Congress after the Nov. 3 midterm elections,…
‘It’s All About the Patient’: ASNC President-Elect Looks to the Future of Nuclear Cardiology
In a video interview with Cardiovascular Business, ASNC-Elect President Andrew J. Einstein,…
ASNC Continues Opposition to H-1B Fees for Physicians
ASNC has joined a coalition of medical societies in opposing the Department…


